Billing (Press 1)




Billing Questions (Press 1)


Pay Your BIll Online


Connect via Telehealth


What Do You Hope to See Happening in Urology in 2021?

Dr. Neal Shore, MD, FACS

An excerpt from a recent article including Dr. Shore in the Urology Times (click here to read full article)

“I’m excited for potential FDA approval of 2 intravascular therapies for high-risk, non–muscle invasive bladder cancer [that is] unresponsive to BCG. These include nadofaragene firadenovec, an investigational gene therapy by FerGene, and oportuzumab monatox, a recombinant fusion protein by Sesen Bio. These 2 therapies will join pembrolizumab [Keytruda], the first drug for patients unresponsive to BCG that was just approved this year that could allow these patients to avoid a cystectomy.

In prostate cancer, we should have the announcement of the phase 3 VISION trial results of the novel therapeutic drug Lu-PSMA-617, a prostate-specific membrane antigen–targeting agent used to deliver radionuclide therapy for the treatment of advanced prostate cancer patients with [metastatic castration-resistant prostate cancer]. This would add another new therapeutic with a distinct mechanism of action.

But I’m most excited about the FDA approval of the first and only oral [gonadotropin-releasing hormone] antagonist, relugolix (Orgovyx, Myovant Sciences), for androgen deprivation for patients with advanced prostate cancer. It offers enhanced cardiovascular safety and an enhanced mechanism of action as an antagonist. It has faster, more profound testosterone suppression and a shorter course of therapy.

Fortunately, our research program has not been deterred by the pandemic, and we’ve not experienced any setbacks in monitoring our patients or in accruing new subjects.

Our clinic, both outpatient and inpatient schedules, has been very busy. But personally, I haven’t been traveling anywhere near the degree I was, so it has allowed me to be more productive regarding my educational endeavors and
my research.”

How Can We Help You?

Language Assistance Services for Individuals With Limited English Proficiency

ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 843-347-2450.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 843-347-2450.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 843-347-2450.

注意:如果您使用繁體中文,您可以免費獲得語言援助服務。請致電 843-347-2450。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn.  Gọi số 843-347-2450.

주의:  한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 843-347-2450. 번으로 전화해 주십시오.

ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 843-347-2450.

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 843-347-2450.

ՈՒՇԱԴՐՈՒԹՅՈՒՆ՝  Եթե խոսում եք հայերեն, ապա ձեզ անվճար կարող են տրամադրվել լեզվական աջակցության ծառայություններ:  Զանգահարեք 843-347-2450:

ATTENZIONE: In caso la lingua parlata sia l’italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 843-347-2450.

فارسیتوجه: اگر به زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با


ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis.  Ligue para 843-347-2450.

ملحوظة:  إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان.  اتصل برقم 1-_843-347-2450_____________ (رقم هاتف الصم والبك).

ध्यान दें:  यदि आप हिंदी बोलते हैं तो आपके लिए मुफ्त में भाषा सहायता सेवाएं उपलब्ध हैं। 843-347-2450 पर कॉल करें।


ATTENTION: Si vous parlez français, des services d’aide linguistique vous sont proposés gratuitement.  Appelez le 843-347-2450.